Cyted Health Shares EndoSign Clinical Validation Results
New data from the DETECT-ME study demonstrate the effectiveness of the EndoSign Barrett's Esophagus Test.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Would you trust a non-invasive diagnostic test as much as a traditional medical procedure?
Cyted Health recently revealed clinical validation results for its EndoSign test, a diagnostic tool for Barrett's esophagus. The findings were presented during the American College of Gastroenterology Annual Scientific Meeting.
Why it matters
The test aims to identify patients who require referral for endoscopy, potentially expanding diagnostic access for individuals at risk of Barrett's esophagus. By using a non-sedated cell collection procedure, the process seeks to simplify screening.
The DETECT-ME study enrolled 324 participants across 18 clinical sites in the United States to validate the EndoSign Cell Collection Device. Cyted Health processes the subsequent molecular testing at its CLIA-certified and CAP-accredited lab.
The players
Cyted Health
This company is a diagnostics developer based in Cambridge that focuses on early detection technology.
American College of Gastroenterology
This medical organization represents specialists dedicated to the study and treatment of digestive tract disorders.
The details
The test features a cell collection procedure performed without the need for sedation, followed by specialized molecular testing. Researchers compared the performance of the EndoSign device against the traditional standard of endoscopy and biopsy to determine its clinical utility.
Timeline
October 2026: The DETECT-ME data was presented at the ACG Annual Scientific Meeting.
The Big Picture
The results of the DETECT-ME clinical study provide a path toward non-invasive diagnostics for gastrointestinal conditions. This study follows a pattern of research aimed at utilizing molecular testing to improve patient triage.
The EndoSign test offers a potential alternative to traditional endoscopy by removing the need for sedation during the cell collection procedure. This may simplify the diagnostic process for patients who are at risk for Barrett's esophagus.
The takeaway
Advancements in non-invasive molecular testing continue to change how clinicians screen for gastrointestinal conditions. Patients should consult their primary care providers about whether new screening options are appropriate for their specific health needs.
Further reading
For more information on diagnostic advancements, visit the Cancer section.
Source note: This article includes information reported by Business Weekly.
Live Poll
Would you trust a non-invasive diagnostic test as much as a traditional medical procedure?
